Meltem Zeytinoglu
Executive Medical Director Eli Lilly & Co.
Dr. Meltem Zeytinoglu is the Executive Medical Director at Eli Lilly and Company. She specializes in clinical trials, drug development, obesity, type 2 diabetes mellitus, and healthy metabolic aging. Dr. Zeytinoglu has extensive experience in endocrinology, including roles at UChicago Medicine and a tenure at Johns Hopkins Bloomberg School of Public Health. Her research focuses on improving the management of chronic metabolic conditions in older adults and has been instrumental in advancing the development of new therapies for obesity and related conditions.
Seminars
Wednesday 9th December 2026
Unlocking Superior Weight Loss Outcomes Through Amylin Agonists & Next-Generation Multi-Hormone Therapies
9:30 am
- Advancing next-generation amylin agonists to enhance appetite control and satiety, unlocking greater weight loss efficacy beyond traditional GLP-1 pathways
- Identifying the patients most likely to benefit from amylin-based therapies by evaluating clinical evidence, response patterns and emerging opportunities for targeted treatment selection
- Optimizing amylin-GLP-1 combination strategies to maximize weight loss outcomes while improving tolerability and supporting long-term treatment adherence
